39. (New) A method of treating the abnormality of high acidity in the vagina, wherein the vaginal pH value is lower than 4.0, comprising administering vaginally to a subject in need a composition comprising an effective amount of one or more amino acids and/or physiologically acceptable salts thereof, and one or more pharmaceutical carriers; if necessary, the pH value of the composition is adjust to be in the range of 4.0-8.0.

40. (New) A method according to Claim 39, wherein the said amino acids and/or physiologically acceptable salt thereof are selected from the group consisting of glutamic acid, glutamine, aspartic acid, asparagine, isoleucine, methionine, phenylalanine, tyrosine, valine, leucine, proline, threonine, cysteine, alanine, glycine, serine, lysine, arginine, tryptophane and histidine.

B1

41. (New) The method according to Claim 39, wherein the said amino acids are selected from the group consisting of glutamic acid, glutamine, aspartic acid, asparagine, isoleucine, phenylalanine, valine, leucine, proline and threonine.

42. (New) A method according to Claim 39, wherein the said method is for treating vaginitis with abnormally high vaginal acidity of a pH value less than 4.0.

43. (New) A method according to Claim 39, where the said method is for treating fungal vaginitis with abnormally high vaginal acidity of a pH value less than 4.0.

44. (New) The method according to Claim 39, wherein the said composition is in the form of viscous gels, lotion, tablets,

effervescent tablets, suppositories, emulsion, ointments or micro-capsules.

45. (New) The method according to Claim 44, wherein when the composition is in the form of viscous gel, lotion or emulsion, the total content of amino acids and/or the physiologically acceptable salts thereof is in the range of 30-350mmol/L.

46. (New) The method according to Claim 45, wherein the total content of amino acids and/or the physiologically acceptable salts thereof is in the range of 80-200mmol/L.

47. (New) The method according to Claim 39, wherein the said physiologically acceptable salts of amino acids is the sodium salt, potassium salt, calcium salt, magnesium salt of amino acids.

48. (New) The method according to Claim 47, wherein the said physiologically acceptable salt of amino acid is the sodium salt of amino acid.

B1 Cont

49. (New) The method according to Claim 39, wherein the composition further comprises:

oligopeptide and/or polypeptide, the oligopeptide and polypeptide are the oligopeptide and polypeptide contained in tryptone or other kind of hydrolysis products of proteins or yeast extracts.

50. (New) The method according to Claim 39, wherein the composition further comprises:

one or more pharmaceutical alkalis selected from the group consisting of calcium hydroxide, magnesium hydroxide, sodium carbonate, sodium bicarbonate, sodium lactate, sodium citrate, sodium acetate, calcium carbonate, potassium bicarbonate, sodium

phosphate, disodium hydrogen phosphate, dipotassium hydrogen phosphate.

51. (New) The method according to Claim 49, wherein the composition further comprises:

one or more pharmaceutical alkalis selected from the group consisting of calcium hydroxide, magnesium hydroxide, sodium carbonate, sodium bicarbonate, sodium lactate, sodium citrate, sodium acetate, calcium carbonate, potassium bicarbonate, sodium phosphate, disodium hydrogen phosphate, dipotassium hydrogen phosphate.

52. (New) The method according to Claim 39, wherein the composition further comprises:

one or more anti-fungal drugs selected from the group consisting of Miconazole, Ketoconazole, Treconazole, Itraconazole and Fluconazole, Clotrimazole, 5-Flucytosine, Mikostatine.

B' Cont

53. (New) The method according to Claim 49, wherein the composition further comprises:

one or more anti-fungal drugs selected from the group consisting of Miconazole, Ketoconazole, Treconazole, Itraconazole and Fluconazole, Clotrimazole, 5-Flucytosine, Mikostatine.

54. (New) The method according to Claim 50, wherein the composition further comprises:

one or more anti-fungal drugs selected from the group consisting of Miconazole, Ketoconazole, Treconazole, Itraconazole and Fluconazole, Clotrimazole, 5-Flucytosine, Mikostatine.

55. (New) The method according to Claim 51, wherein the composition further comprises:

one or more anti-fungal drugs selected from the group consisting of Miconazole, Ketoconazole, Treconazole, Itraconazole and Fluconazole, Clotrimazole, 5-Flucytosine, Mikostatine.

56. (New) The method according to Claim 39, wherein the composition further comprises:

one or more plant extracts selected from the group consisting of Radix Sophorae Flavescentis, Monnieri Fructus Cnidii, Herba Hedyotis Difffusae, Desmodium styracifolium, and Cortex Phellodendri.

57. (New) The method according to Claim 49, wherein the composition further comprises:

one or more plant extracts selected from the group consisting of Radix Sophorae Flavescentis, Monnieri Fructus Cnidii, Herba Hedyotis Difffusae, Desmodium styracifolium, and Cortex Phellodendri.

58. (New) The method according to Claim 50, wherein the composition further comprises:

one or more plant extracts selected from the group consisting of Radix Sophorae Flavescentis, Monnieri Fructus Cnidii, Herba Hedyotis Diffusae, Desmodium styracifolium, and Cortex Phellodendri.

59. (New) The method according to Claim 51, wherein the composition further comprises:

one or more plant extracts selected from the group consisting of Radix Sophorae Flavescentis, Monnieri Fructus

Cnidii, Herba Hedyotis Diffusae, Desmodium styracifolium, and Cortex Phellodendri.

60. (New) The method according to Claim 52, wherein the composition further comprises:

one or more plant extracts selected from the group consisting of Radix Sophorae Flavescentis, Monnieri Fructus Cnidii, Herba Hedyotis Diffusae, Desmodium styracifolium, and Cortex Phellodendri.

61. (New) The method according to Claim 53, wherein the composition further comprises:

one or more plant extracts selected from the group consisting of Radix Sophorae Flavescentis, Monnieri Fructus Cnidii, Herba Hedyotis Diffusae, Desmodium styracifolium, and Cortex Phellodendri.

62. (New) The method according to Claim 54, wherein the composition further comprises:

B1 Cont

one or more plant extracts selected from the group consisting of Radix Sophorae Flavescentis, Monnieri Fructus Cnidii, Herba Hedyotis Diffusae, Desmodium styracifolium, and Cortex Phellodendri.

63. (New) The method according to Claim 55, wherein the composition further comprises:

one or more plant extracts selected from the group consisting of Radix Sophorae Flavescentis, Monnieri Fructus Cnidii, Herba Hedyotis Diffusae, Desmodium styracifolium, and Cortex Phellodendri.